Kahimmune Therapeutics: Funding, Investors & Team (Sep 2026)
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to create next-generation immuno-oncology medicines. Kahimmune uses revolutionary insights into the "dark genome" to identify novel neoantigens, resulting in innovative cancer vaccinations developed for synergistic combination therapy.
Kahimmune Therapeutics has raised $120k across 1 funding round on record, the most recent an undisclosed round of $120k announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kahimmune Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Kahimmune Therapeutics Funding Rounds
Kahimmune Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Kahimmune Therapeutics Funding Compared to Other Biotechnology Startups
Kahimmune Therapeutics' latest round of $120k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kahimmune Therapeutics in Biotechnology and Avignon
Companies Similar to Kahimmune Therapeutics
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Kahimmune Therapeutics Funding FAQs
What does Kahimmune Therapeutics do?
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to create next-generation immuno-oncology medicines. Kahimmune uses revolutionary insights into the "dark genome" to identify novel neoantigens, resulting in innovative cancer vaccinations developed for synergistic combination therapy.
How much funding has Kahimmune Therapeutics raised?
Kahimmune Therapeutics has raised $120k across 1 round on record. The most recent is an undisclosed round of $120k announced in Apr 2026.
When did Kahimmune Therapeutics last raise funding?
Kahimmune Therapeutics' most recent funding round on record is an undisclosed round of $120k, announced in Apr 2026.
Who founded Kahimmune Therapeutics?
FundedIQ lists Philippe Villain (Founder) at Kahimmune Therapeutics.
Where is Kahimmune Therapeutics headquartered?
Kahimmune Therapeutics is based in Avignon, Provence-Alpes-Cote d'Azur, France.
How many employees does Kahimmune Therapeutics have?
Kahimmune Therapeutics is in the 1-10 employee band.
How does Kahimmune Therapeutics' funding compare to other Biotechnology startups?
Kahimmune Therapeutics' latest round of $120k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Kahimmune Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kahimmune Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.